This study is testing a drug called olezarsen for children aged 2 to 17 years old who have Familial Chylomicronemia Syndrome (FCS). FCS is a rare genetic condition that causes very high levels of fats (triglycerides) in the blood. Olezarsen is given as a shot under the skin. The main goal is to see how much olezarsen can lower fasting triglycerides after 6 months. The study is currently enrolling about 12 participants. To join, a parent or guardian must give permission, and the child must also agree if they are old enough to understand. You must also be able to follow all study procedures.

Study design

This is a Phase 3, multi-center, open-label study, meaning both you and the study team will know you are receiving olezarsen. It plans to enroll about 12 participants.

What's involved

The study involves a 1-month screening period, a 1-year treatment period, an optional 1-year extension, and a 3-month follow-up period.

Compensation

Not stated in the trial record.

Follow-up

Participants will be followed for 3 months after their treatment period ends.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.